Current recommendations for the treatment of non -small-cell lung cancer with special focus to therapy of advanced NSCLC according to ESMO and NCCN guidelines and Blue Book
2015
Abstract
Bronchogenic carcinoma is a disease with high incidence, and also in the treatment of used medical procedures setting standards of care and enabling comprehensive view of therapy. These treatments react to new drugs or procedures based on evidence-based medicine, and last but not least, they also have educational significance.
Most often it is updated guidelines European Society of Medical Oncology (ESMO) and the US company National Comprehensive Cancer Network (NCCN), which are updated detail as possible, sometimes even several times during the year. Blue Book (Principles of cytostatic treatment of malignant cancer diseases COS CzMA) contains recommendations for the Czech Republic.